Lexicon Pharmaceuticals, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Lexicon Pharmaceuticals, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Cash Locked Ratio: Money owed to suppliers is larger than money owed by customers plus stock: $1 per $100 of sales comes from others' credit, against $7,458 from others' credit three years earlier. Less money tied up than 90% of Healthcare companies in United States.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
—Data incomplete
Cash Locked Ratio
−$1Money owed to suppliers is larger than money owed by customers plus stock: $1 per $100 of sales comes from others' credit, against $7,458 from others' credit three years earlier.
Less money tied up than 90% of Healthcare companies in United States.
Growth quality
Steadiness Ratio
3/3 · 1/3Sales grew in 3 of the last 3 years; profit grew in 1 of 3.
Steadier than 69% of Healthcare companies in United States.
Growth Efficiency Ratio
$104Sales grew 35,729% in 3 years; of every extra $100 of sales, $104 became extra profit.
Higher than 81% of Healthcare companies in United States.
Asset Productivity Ratio
+35729% / -5%In 3 years sales changed by +35729% while total assets changed by -5%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
-14.8×Operating cash was negative last year, while some debt falls due within a year.
Higher than 50% of Healthcare companies in United States.
Cash Cushion Ratio
+5%Cash, after subtracting all debt, equals 5% of its market value (net cash).
Lower than 57% of Healthcare companies in United States.
Tangible Assets Ratio
76%Of every $100 the company owns, $76 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
Less tangible than 57% of Healthcare companies in United States.
Tangible Net Worth Ratio
59%Of every $100 of net worth, $59 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 51% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (13)
Lexicon Pharmaceuticals, Inc. made a loss over the last year. Lexicon Pharmaceuticals, Inc. owes $0.30 for every $1 it owns. Lexicon Pharmaceuticals, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossLexicon Pharmaceuticals, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
3.62The share price is 3.62 times Lexicon Pharmaceuticals, Inc.'s book value per share, higher than 62% of Healthcare companies in United States.
Market cap
$632 MThe total market value of all of Lexicon Pharmaceuticals, Inc.'s shares at today's price (share price × number of shares), larger than 58% of Healthcare companies in United States. PosiCap size class: Mini Cap.
Net worth (book value)
$175 MWhat Lexicon Pharmaceuticals, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$0.39Net worth divided by the number of shares. The share price of $1.42 is 3.6 times this, which is the P/B above.
Return on equity (ROE)
-40.2%Lexicon Pharmaceuticals, Inc. lost 40.2% of its shareholders' money over the last year, higher than 54% of Healthcare companies in United States.
Owes vs Owns
0.30×Lexicon Pharmaceuticals, Inc. owes $0.30 for every $1 it owns (low), lower than 60% of Healthcare companies in United States.
Dividend yield
NoneLexicon Pharmaceuticals, Inc. does not currently pay a dividend.
Revenue growth
+60%Revenue rose 60% in the year to Dec 2025, and grew 610% a year on average over 3 years.
Profit growth
LossLexicon Pharmaceuticals, Inc. made a loss in each of the last two years.
Profit margin
-101.1%Lexicon Pharmaceuticals, Inc. lost $101 for every $100 of revenue.
Interest cover
Not coveredLexicon Pharmaceuticals, Inc.'s operating profit did not cover its interest costs in the year to Dec 2025.
Cash vs debt
Net cashLexicon Pharmaceuticals, Inc. held $33 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Lexicon Pharmaceuticals, Inc.: $632 M ÷ $175 M (30 Jun 2026) = 3.6.
What is Lexicon Pharmaceuticals, Inc.'s return on equity?
Lexicon Pharmaceuticals, Inc. lost 40.2% of its shareholders' money over the last year, higher than 54% of Healthcare companies in United States.
How much does Lexicon Pharmaceuticals, Inc. owe compared with what it owns?
Lexicon Pharmaceuticals, Inc. owes $0.30 for every $1 it owns (low), lower than 60% of Healthcare companies in United States.
Does Lexicon Pharmaceuticals, Inc. pay a dividend?
No. Lexicon Pharmaceuticals, Inc. does not currently pay a dividend.
Is Lexicon Pharmaceuticals, Inc.'s revenue growing?
Revenue rose 60% in the year to Dec 2025, and grew 610% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.